Cargando…

OR28-5 Bile Acid Sequestration Accelerates Glucagon Receptor-Mediated Body Weight Loss in Obese Mice

Glucagon, an essential regulator of glucose and lipid metabolism, also promotes weight loss. Previously, we reported that chronic glucagon receptor (GCGR) activation increased energy expenditure and plasma bile acid (BA) levels. Hepatic Farnesoid X Receptor (FXR) has been associated with this GCGR-B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Teayoun, Nason, Shelly, Antipenko, Jessica, Presedo, Natalie, Finan, Brian, DiMarchi, Richard, Habegger, Kirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554830/ http://dx.doi.org/10.1210/js.2019-OR28-5

Ejemplares similares

SAT-655 Bile Acid Sequestration Synergistically Accelerates Glucagon Receptor-Stimulated Body Weight Loss in Diet-Induced Obese Mice
por: Kim, Teayoun, et al.
Publicado: (2020)

Hypothalamic Glucagon Receptors Regulate Feeding in Mice
por: Cunningham, Stephen E, et al.
Publicado: (2021)

Glucagon receptor signaling regulates weight loss via central KLB receptor complexes
por: Nason, Shelly R., et al.
Publicado: (2021)

Scientific and Regulatory Considerations for the Approval of the First Generic Glucagon
por: Pang, Eric, et al.
Publicado: (2021)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

OR22-3 Closed-Loop Glucagon Pump: A Novel and Effective Strategy for Post-Bariatric Hypoglycemia
por: Mulla, Christopher, et al.
Publicado: (2019)

MON-LB115 Ready-To-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia in a Clinical Research Setting
por: Aronson, Ronnie, et al.
Publicado: (2020)

OR28-1 Role of Mineralocorticoid Receptor in Metabolic Syndrome
por: Ferguson, Daniel, et al.
Publicado: (2019)

A Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonist in Kidney Transplant Recipients With Type 2 Diabetes
por: Sato, Tetsuhiko, et al.
Publicado: (2021)

MON-163 Lowering of Circulating FGF21 by Modulation of Bile Acid Metabolism in Healthy Males
por: Al-Khaifi, Amani, et al.
Publicado: (2019)

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020)

SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus
por: Fazeli, Sasan, et al.
Publicado: (2019)

OR26-07 Mild Physiologic Hyperglycemia Does Not Affect Glucose Mediated but Impairs Insulin-Mediated Suppression of Plasma Glucagon in Healthy Normal Glucose Tolerant Subjects
por: Tripathy, Devjit, et al.
Publicado: (2020)

MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure
por: Pettus, Jeremy H, et al.
Publicado: (2020)

OR28-4 Spontaneous Autoimmune Diabetes in Humanized Mice Carrying Human Type 1 Diabetes Susceptibility
por: Imam, Shahnawaz, et al.
Publicado: (2019)

OR28-2 The Ldb1 Transcriptional Co-regulator Is Required for Establishment, Development, and Survival of the Pancreatic Endocrine Lineage
por: Toren, Eliana, et al.
Publicado: (2019)

OR28-6 Short-Term Mifepristone Treatment Improves Hepatic and Adipose Tissue Insulin Sensitivity in Overweight and Obese Subjects with Glucose Intolerance
por: Grewal, Shivraj, et al.
Publicado: (2019)

MON-LB032 Real World Evidence Data on the Role of Sodium/Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist in Chronic Kidney Disease Stage 3 Patients beyond Glycemic Control, at Glycemia Clinic- Kuwait
por: Shaghouli, Amna, et al.
Publicado: (2019)

OR28-3 A Mutation in KCNK16 Segregating with Autosomal Dominant Non-Ketotic Diabetes Drastically Increases TALK-1 Membrane Current: A Novel Gene for MODY?
por: Johnson, Stephanie, et al.
Publicado: (2019)

High-Fat Diet Accelerates Pathological Progression and Intestinal Inflammation in a Type 2 Diabetes Rodent Model
por: Reilly, Austin, et al.
Publicado: (2021)

Early Onset Acceleration of Fetal Growth in Gestational Diabetes Mellitus: Deciding About When and Whom to Screen for Preventing Fetal Macrosomia
por: Mirabelli, Maria, et al.
Publicado: (2021)

A Novel Homozygous WRN Mutation Identified in a Middle Aged Man With Diabetes Mellitus Complicated By Multiple Features of Accelerated Aging
por: Jaafar, Batoul, et al.
Publicado: (2021)

Prospective Longitudinal Study Evaluating Comprehensive Metabolic and Life Style Characteristics of Pancreas Transplantation Recipients
por: Kaur, Ravinder Jeet, et al.
Publicado: (2021)

SAT-641 Self-Reported Psychological Stress and Glucose Variability in Type 1 Diabetes on Sensor Augmented Pump over 5 Weeks
por: Kaur, Ravinder Jeet, et al.
Publicado: (2020)

OR24-4 Targeting Hyperglucagonemia Reverses Glucagon Resistance
por: Bernal-Mizrachi, Ernesto, et al.
Publicado: (2022)

OR34-06 Gliclazide Restores Appropriate Glucagon Suppression During OGTT In MODY3 & MODY1 Patients: Results Of The “Glucagon In MODY” Study
por: Spiliotis, Ioannis Ilias, et al.
Publicado: (2023)

RF04 | PSUN233 Design of an Ultra-Stable Insulin/Glucagon Fusion Protein
por: Grabowski, Rachel, et al.
Publicado: (2022)

LBODP066 A Conservative Approach To The Management Of Glucagon Receptor (GCCR) Mutation (Mahvash Syndrome)
por: Morgenthau, Ari, et al.
Publicado: (2022)

THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes
por: Reddy Ankireddypalli, Anvitha, et al.
Publicado: (2023)

MON-LB024 Episodic Hypoglycemia in Non-Diabetics: Differentiating Distressing from Deadly
por: Windham, Mary, et al.
Publicado: (2019)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

MON-158 Association between Famine Exposure in Early Life with Insulin Resistance and β-cell Dysfunction in Adulthood
por: Wang, Yuying, et al.
Publicado: (2019)

MON-159 Increased Gluconeogenesis and Lower Glycogenolysis in Patients with Non-Selective Compared Selective Insulin Resistance
por: Sekizkardes, Hilal, et al.
Publicado: (2019)

MON-164 The Non-insulin-based METS-IR Index Combined With Liver Transaminases Improves Prediction Of Fatty Liver And Fibrosis
por: Bello-Chavolla, Omar, et al.
Publicado: (2019)

MON-162 Hepatic DNA Damage Induced by ENDS Is Associated with Decreased Levels of NAD+
por: Espinoza-Derout, Jorge, et al.
Publicado: (2019)

MON-150 Phone Call Reminders and Mobile Health Apps: Do They Help Our Diabetic Patients?
por: Lu, Kevin, et al.
Publicado: (2019)

MON-182 Adaptable Amperometric Biosensor Platforms for the Diagnosis of Endocrine Disorders
por: Labban, Najwa, et al.
Publicado: (2019)

MON-129 An Unusual LMNA Mutation Causing a Complex Phenotype: When the Genetic Diagnosis Uncovers Novel Features
por: Andrade, Natália, et al.
Publicado: (2019)

MON-178 Vitamin D Treatment of Patients with Type 1 Diabetes Reduces RORy, FoxP3 and CD4 Gene Expression in T Helper Cells
por: Penna-Martinez, Marissa, et al.
Publicado: (2019)

MON-154 Abnormal Glucose Homeostasis in Spinal Muscular Atrophy (SMA) Leading to a Transient Episode of Diabetic Ketoacidosis (DKA)
por: Hossain, Sabina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n4ljcj2lrg7uk80lkg74v5o649